Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab plus nab-paclitaxel vs placebo plus nab-paclitaxel in metastatic TNBC
CTR20182403Phase 3Active
- Sponsor
- CSPC Ouyi Pharmaceutical
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by CSPC Ouyi Pharmaceutical. Started Dec 2018; status: active.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on CTR20182403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20182403.